end,filed,form,Name,Ticker,CIK,Currency,AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent,AccountsPayableCurrent,AccruedBonusesCurrent,AccruedLiabilitiesCurrent,AccruedProfessionalFeesCurrent,AdditionalPaidInCapitalCommonStock,AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,AllocatedShareBasedCompensationExpense,AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Assets,AssetsCurrent,Cash,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect,ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1,CommonStockCapitalSharesReservedForFutureIssuance,CommonStockParOrStatedValuePerShare,CommonStockSharesAuthorized,CommonStockSharesIssued,CommonStockSharesOutstanding,CommonStockSharesSubscribedButUnissued,CommonStockSharesSubscriptions,CommonStockValue,ContractWithCustomerLiabilityCurrent,CostsAndExpenses,DebtInstrumentInterestRateStatedPercentage,DeferredCosts,EarningsPerShareBasicAndDiluted,FairValueAdjustmentOfWarrants,GrantsReceivableCurrent,IncomeTaxExpenseBenefit,IncreaseDecreaseInAccountsPayable,IncreaseDecreaseInAccountsReceivable,IncreaseDecreaseInDeferredRevenue,IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities,IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets,InterestExpense,InterestPaidNet,Liabilities,LiabilitiesAndStockholdersEquity,LiabilitiesCurrent,LongTermDebt,LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths,LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear,LongTermNotesPayable,NetCashProvidedByUsedInFinancingActivities,NetCashProvidedByUsedInOperatingActivities,NetIncomeLoss,NotesPayable,NotesPayableCurrent,NotesReduction,OperatingIncomeLoss,OtherAccruedLiabilitiesCurrent,PaymentsForRepurchaseOfInitialPublicOffering,PaymentsRelatedToTaxWithholdingForShareBasedCompensation,PreferredStockParOrStatedValuePerShare,PreferredStockSharesAuthorized,PreferredStockSharesIssued,PreferredStockSharesOutstanding,PrepaidExpenseAndOtherAssetsCurrent,PrepaidExpenseCurrent,ProceedsFromIssuanceOfCommonStock,ProceedsFromNotesPayable,ProceedsFromStockOptionsExercised,RepaymentsOfNotesPayable,ResearchAndDevelopmentExpense,RetainedEarningsAccumulatedDeficit,RevenueFromContractWithCustomerExcludingAssessedTax,SellingGeneralAndAdministrativeExpense,ShareBasedCompensation,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1,StockholdersEquity,StockholdersEquityNoteStockSplitConversionRatio1,StockIssuedDuringPeriodSharesStockOptionsExercised,StockIssuedDuringPeriodValueConversionOfUnits,StockIssuedDuringPeriodValueNewIssues,StockIssuedDuringPeriodValueStockOptionsExercised,TreasuryStockValue,WarrantsAndRightsOutstanding,WeightedAverageNumberOfShareOutstandingBasicAndDiluted,ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod,StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2020-12-31,2021-03-31,10-K,"INHIBIKASE THERAPEUTICS, INC.",IKT,CIK0001750149,USD,,1720680.0,,632934.0,383286.0,24805929.0,,,,14782706.0,14782706.0,13953513.0,13953513.0,,,4318357.0,0.001,30000000.0,10050849.0,10050849.0,,,10051.0,2325741.0,,,,,,,,,,,,,,,4998350.0,14782706.0,4721889.0,,,,276461.0,,,,318995.0,42534.0,,,49079.0,,,0.001,10000000.0,0.0,0.0,54837.0,774356.0,,,,,,-15031624.0,,,,,,9784356.0,,,,,,,,,,
2021-03-31,2021-05-17,10-Q,"INHIBIKASE THERAPEUTICS, INC.",IKT,CIK0001750149,USD,1342415.0,715016.0,,627399.0,82802.0,25695203.0,591124.0,591124.0,4386985.0,11874035.0,11871252.0,9609631.0,9609631.0,-4343882.0,,4386985.0,0.001,100000000.0,10059849.0,10059849.0,,,10060.0,1251349.0,4032436.0,,2783.0,-0.26,237768.0,332774.0,0.0,-1008447.0,332774.0,-1074392.0,-5535.0,-200581.0,11797.0,11797.0,3837464.0,11874035.0,3588553.0,1243700.0,248911.0,994789.0,248911.0,-409662.0,-3934220.0,-2637068.0,1243700.0,994789.0,,-2625271.0,3322.0,,,0.001,10000000.0,0.0,0.0,1216173.0,712674.0,,,,409662.0,2431860.0,-17668692.0,1407165.0,1600576.0,591124.0,68628.0,6.82,8036571.0,,,,60391.0,,,,10053949.0,,
2021-06-30,2021-08-16,10-Q,"INHIBIKASE THERAPEUTICS, INC.",IKT,CIK0001750149,USD,1769997.0,897226.0,101907.0,872771.0,,67334089.0,322483.0,,,49215879.0,,46836556.0,46836556.0,,3.75,5186570.0,0.001,100000000.0,25133345.0,25133345.0,,,25134.0,142619.0,3991405.0,,,-0.22,239415.0,586581.0,,,,,,,7811.0,,2161527.0,49215879.0,1912616.0,248911.0,248911.0,,248911.0,,,-2636179.0,248911.0,,,-2628368.0,5497.0,,,0.001,10000000.0,0.0,0.0,833963.0,958779.0,,,,,2382433.0,-20304871.0,1363037.0,1608972.0,,,2.02,47054352.0,,,,,-43295.0,,,12241935.0,21854.0,
2021-09-30,2021-11-15,10-Q,"INHIBIKASE THERAPEUTICS, INC.",IKT,CIK0001750149,USD,2458811.0,553801.0,152860.0,1905010.0,,67912392.0,352419.0,,,45869201.0,,44845950.0,44845950.0,,3.75,5191957.0,0.001,100000000.0,25155198.0,25155198.0,,,25155.0,0.0,4799499.0,,,-0.18,181762.0,217482.0,,,,,,,157.0,,2707722.0,45869201.0,2707722.0,248911.0,248911.0,,0.0,,,-4471197.0,248911.0,248911.0,,-4471040.0,11518.0,,,0.001,10000000.0,0.0,0.0,541388.0,264381.0,,,,,3154553.0,-24776068.0,328459.0,1644946.0,,,6.82,43161479.0,,,,,44143.0,,,25143559.0,,
